arrow
I

Ira M. Jacobson

university of buenos aires
H指数:87
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies

塞拉德尔帕(Seladelpar)在原发性胆汁性胆管炎合并代偿期肝硬化患者中的疗效与安全性:来自RESPONSE和ASSURE研究的数据

2026-05-010
PRE
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey

妊娠期丙型肝炎治疗:医师观点——一项跨国多专科调查

2026-04-060
PRE
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities

四个人口最多美国城市中,初级保健提供者对代谢功能障碍相关脂肪性肝病(MASLD)的认知

2026-03-110
OAAI
Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States

Wong, R.J.; Gish, R.G.; Jacobson, I.M.; Lim, J.K.; Rock, M.; Kinyik-Merena, C.; Ma, H.; Smith, N.; Kim, C. 双重反向测试及与治疗衔接对慢性丁型肝炎病毒感染临床结局的影响。J. Viral Hepat. 2026, 33, e70119. [Google Scholar] [CrossRef] [PubMed]

2026-01-011
OAAI
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial

Levy, C.; Abouda, G.F.; Bilir, B.M.; Bonder, A.; Bowlus, C.L.; Campos-Varela, I.; Cazzagon, N.; Chandok, N.; Cheent, K.; Cortez-Pinto, H.; 等. Elafibranor在原发性硬化性胆管炎中的安全性与有效性:ELMWOOD II期随机对照试验. J. Hepatol. 2025. [Google Scholar] [CrossRef] [PubMed]

2025-05-100
OAAI
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses
2024-04-011
OAAI
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
2024-01-0123
OAAI
Efficacy and safety of the siRNAJNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2btrial

siRNAJNJ-73763989和衣壳组装调节剂JNJ-56136379 (bersacapavir) 与核苷 (酸) 类似物治疗慢性乙型肝炎病毒感染 (REEF-1) 的疗效和安全性: 多中心,双盲,主动控制,随机,2期btrial

2023-09-0125
PRE
Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection
2022-11-0125
OA
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
2022-09-0123
PRE